ARDX
Ardelyx·NASDAQ
--
--(--)
--
--(--)
ARDX fundamentals
Ardelyx (ARDX) released its earnings on Feb 19, 2026: revenue was 125.22M (YoY +7.82%), beat estimates; EPS was 0 (YoY -100.00%), missed estimates.
Revenue / YoY
125.22M
+7.82%
EPS / YoY
0
-100.00%
Report date
Feb 19, 2026
ARDX Earnings Call Summary for Q4,2025
- IBSRELA Supercharge: 73% revenue growth in 2025 to $274M, with 2026 guidance of $410-430M (50%+ YoY). CIC label expansion on track for 2029 $1B target.
- XPHOZAH Resilience: 9% dispense growth post-Medicare loss, non-Medicare paid dispenses up 41%. Specialty pharmacy network adoption boosts fill rates.
- Pipeline Power: $71.5M R&D investment in 2025 for CIC trial and 531 development. 531 shows 10x potency, poised for Phase I in 2026.
- IP Fortification: New formulation patent listed in Orange Book until 2042, supporting long-term franchise value.
- Cash Clarity: $265M cash on hand, positive cash flow in last 2 quarters, with 2026 OpEx up 25% to $520M.
EPS
Actual | -0.25 | -0.28 | -0.2 | -0.32 | -0.34 | -0.45 | -0.42 | -0.31 | -0.21 | -0.19 | -0.14 | 0.06 | -0.13 | -0.08 | 0.03 | -0.12 | -0.11 | -0.07 | 0 | 0.02 | -0.17 | -0.08 | 0 | 0 | ||||||||||
Forecast | -0.2506 | -0.2675 | -0.2827 | -0.2613 | -0.3294 | -0.3654 | -0.3514 | -0.3038 | -0.2212 | -0.1926 | -0.1684 | 0.0023 | -0.1008 | -0.1153 | -0.1076 | -0.0947 | -0.1474 | -0.106 | -0.049 | 0.0041 | -0.1119 | -0.1317 | -0.0579 | 0.013 | ||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +0.24% | -4.67% | +29.25% | -22.46% | -3.22% | -23.15% | -19.52% | -2.04% | +5.06% | +1.35% | +16.86% | +2508.70% | -28.97% | +30.62% | +127.88% | -26.72% | +25.37% | +33.96% | +100.00% | +387.80% | -51.92% | +39.26% | +100.00% | -100.00% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.21M | 1.84M | 2.71M | 1.81M | 6.58M | 1.31M | 1.17M | 1.03M | 468.00K | 2.53M | 4.99M | 44.18M | 11.37M | 22.33M | 56.39M | 34.36M | 46.02M | 73.22M | 98.24M | 116.13M | 74.11M | 97.66M | 110.33M | 125.22M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 550.00K | 1.81M | 1.36M | 1.66M | 1.38M | 940.00K | 1.32M | 875.50K | 875.00K | 2.22M | 3.92M | 23.18M | 10.41M | 15.28M | 22.57M | 34.06M | 36.40M | 55.03M | 86.64M | 109.94M | 78.15M | 81.08M | 100.54M | 118.05M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +120.55% | +1.49% | +99.63% | +8.81% | +378.69% | +39.68% | -10.95% | +17.53% | -46.51% | +13.73% | +27.14% | +90.63% | +9.26% | +46.14% | +149.86% | +0.89% | +26.44% | +33.06% | +13.39% | +5.63% | -5.17% | +20.45% | +9.73% | +6.07% |
Earnings Call
You can ask Aime
What guidance did Ardelyx's management provide for the next earnings period?What does Ardelyx do and what are its main business segments?What is the revenue and EPS growth rate for Ardelyx year over year?What is the market's earnings forecast for Ardelyx next quarter?What is Ardelyx's latest dividend and current dividend yield?Did Ardelyx beat or miss consensus estimates last quarter?What were the key takeaways from Ardelyx's earnings call?What were the key takeaways from Ardelyx’s earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
